Eintrag weiter verarbeiten
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , |
| In: | Blood, 125, 2015, 1, S. 22-32 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Sehn, Laurie H. Gascoyne, Randy D. Sehn, Laurie H. Gascoyne, Randy D. |
|---|---|
| author |
Sehn, Laurie H. Gascoyne, Randy D. |
| spellingShingle |
Sehn, Laurie H. Gascoyne, Randy D. Blood Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity Cell Biology Hematology Immunology Biochemistry |
| author_sort |
sehn, laurie h. |
| spelling |
Sehn, Laurie H. Gascoyne, Randy D. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2014-05-577189 <jats:title>Abstract</jats:title> <jats:p>Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), patients who fail R-CHOP have a dismal outcome. Thus, optimization of front-line therapy, as well as the development of more effective salvage strategies, remains an important objective. Advances in molecular genetics have vastly improved our understanding of the biological diversity of DLBCL and have led to the discovery of key oncogenic pathways. In addition to the major molecular designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing technologies have unveiled the remarkable complexity of DLBCL and identified unique molecular targets that may be differentially exploited for therapeutic benefit. These findings have translated into a growing list of promising novel agents. Moving forward, it is of paramount importance to recognize the heterogeneity of DLBCL and to investigate these targeted agents within patient populations who are most likely to benefit. It will be necessary to prioritize drugs that affect key driver pathways and to combine them rationally to optimize their benefit. Improved prognostication and the availability of predictive biomarkers will be crucial to allow for the possibility of individualized risk-adapted therapy.</jats:p> Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity Blood |
| doi_str_mv |
10.1182/blood-2014-05-577189 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Chemie und Pharmazie Biologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE0LTA1LTU3NzE4OQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE0LTA1LTU3NzE4OQ |
| institution |
DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
American Society of Hematology, 2015 |
| imprint_str_mv |
American Society of Hematology, 2015 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
sehn2015diffuselargebcelllymphomaoptimizingoutcomeinthecontextofclinicalandbiologicheterogeneity |
| publishDateSort |
2015 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_unstemmed |
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_full |
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_fullStr |
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_full_unstemmed |
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_short |
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_sort |
diffuse large b-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2014-05-577189 |
| publishDate |
2015 |
| physical |
22-32 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), patients who fail R-CHOP have a dismal outcome. Thus, optimization of front-line therapy, as well as the development of more effective salvage strategies, remains an important objective. Advances in molecular genetics have vastly improved our understanding of the biological diversity of DLBCL and have led to the discovery of key oncogenic pathways. In addition to the major molecular designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing technologies have unveiled the remarkable complexity of DLBCL and identified unique molecular targets that may be differentially exploited for therapeutic benefit. These findings have translated into a growing list of promising novel agents. Moving forward, it is of paramount importance to recognize the heterogeneity of DLBCL and to investigate these targeted agents within patient populations who are most likely to benefit. It will be necessary to prioritize drugs that affect key driver pathways and to combine them rationally to optimize their benefit. Improved prognostication and the availability of predictive biomarkers will be crucial to allow for the possibility of individualized risk-adapted therapy.</jats:p> |
| container_issue |
1 |
| container_start_page |
22 |
| container_title |
Blood |
| container_volume |
125 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346155989860357 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:32:46.961Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Diffuse+large+B-cell+lymphoma%3A+optimizing+outcome+in+the+context+of+clinical+and+biologic+heterogeneity&rft.date=2015-01-01&genre=article&issn=1528-0020&volume=125&issue=1&spage=22&epage=32&pages=22-32&jtitle=Blood&atitle=Diffuse+large+B-cell+lymphoma%3A+optimizing+outcome+in+the+context+of+clinical+and+biologic+heterogeneity&aulast=Gascoyne&aufirst=Randy+D.&rft_id=info%3Adoi%2F10.1182%2Fblood-2014-05-577189&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346155989860357 |
| author | Sehn, Laurie H., Gascoyne, Randy D. |
| author_facet | Sehn, Laurie H., Gascoyne, Randy D., Sehn, Laurie H., Gascoyne, Randy D. |
| author_sort | sehn, laurie h. |
| container_issue | 1 |
| container_start_page | 22 |
| container_title | Blood |
| container_volume | 125 |
| description | <jats:title>Abstract</jats:title> <jats:p>Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), patients who fail R-CHOP have a dismal outcome. Thus, optimization of front-line therapy, as well as the development of more effective salvage strategies, remains an important objective. Advances in molecular genetics have vastly improved our understanding of the biological diversity of DLBCL and have led to the discovery of key oncogenic pathways. In addition to the major molecular designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing technologies have unveiled the remarkable complexity of DLBCL and identified unique molecular targets that may be differentially exploited for therapeutic benefit. These findings have translated into a growing list of promising novel agents. Moving forward, it is of paramount importance to recognize the heterogeneity of DLBCL and to investigate these targeted agents within patient populations who are most likely to benefit. It will be necessary to prioritize drugs that affect key driver pathways and to combine them rationally to optimize their benefit. Improved prognostication and the availability of predictive biomarkers will be crucial to allow for the possibility of individualized risk-adapted therapy.</jats:p> |
| doi_str_mv | 10.1182/blood-2014-05-577189 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Chemie und Pharmazie, Biologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE0LTA1LTU3NzE4OQ |
| imprint | American Society of Hematology, 2015 |
| imprint_str_mv | American Society of Hematology, 2015 |
| institution | DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T17:32:46.961Z |
| match_str | sehn2015diffuselargebcelllymphomaoptimizingoutcomeinthecontextofclinicalandbiologicheterogeneity |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 22-32 |
| publishDate | 2015 |
| publishDateSort | 2015 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Sehn, Laurie H. Gascoyne, Randy D. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2014-05-577189 <jats:title>Abstract</jats:title> <jats:p>Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), patients who fail R-CHOP have a dismal outcome. Thus, optimization of front-line therapy, as well as the development of more effective salvage strategies, remains an important objective. Advances in molecular genetics have vastly improved our understanding of the biological diversity of DLBCL and have led to the discovery of key oncogenic pathways. In addition to the major molecular designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing technologies have unveiled the remarkable complexity of DLBCL and identified unique molecular targets that may be differentially exploited for therapeutic benefit. These findings have translated into a growing list of promising novel agents. Moving forward, it is of paramount importance to recognize the heterogeneity of DLBCL and to investigate these targeted agents within patient populations who are most likely to benefit. It will be necessary to prioritize drugs that affect key driver pathways and to combine them rationally to optimize their benefit. Improved prognostication and the availability of predictive biomarkers will be crucial to allow for the possibility of individualized risk-adapted therapy.</jats:p> Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity Blood |
| spellingShingle | Sehn, Laurie H., Gascoyne, Randy D., Blood, Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity, Cell Biology, Hematology, Immunology, Biochemistry |
| title | Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_full | Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_fullStr | Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_full_unstemmed | Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_short | Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_sort | diffuse large b-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| title_unstemmed | Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2014-05-577189 |